跳至主要内容
临床试验/NCT03679078
NCT03679078
暂停
不适用

An Evaluation of the Tolerance, Compliance, Acceptability and Safety of a New Oral Nutritional Supplement in Dysphagic Patients

Nutricia UK Ltd8 个研究点 分布在 1 个国家目标入组 40 人2018年8月28日

概览

阶段
不适用
干预措施
IDDSI nutritional supplement drink
疾病 / 适应症
Dysphagia
发起方
Nutricia UK Ltd
入组人数
40
试验地点
8
主要终点
Gastrointestinal Tolerance
状态
暂停
最后更新
18天前

概览

简要总结

This study will evaluate the gastrointestinal (GI) tolerance, compliance , acceptability and safety of a ready-to-use oral nutritional supplement drink for patients with dysphagia.

详细描述

Dysphagia is a complex condition common in a number of diagnoses including stroke, Parkinson's disease, head and neck cancer, dementia, learning disabilities and gastric/oesophageal motility disorders. A modified textured diet and/or fluid is considered as an effective intervention in management of dysphagia. The International Dysphagia Diet Standardisation Initiative (IDDSI) have developed a new framework around the terms and descriptors used in the management of individuals with dysphagia. Malnutrition is very common in patients with dysphagia and the use of pre-thickened oral nutritional supplements (ONS) has been found as an effective way to manage this. However, due to impairment in the swallow process, dysphagic patients require pre-thickened oral nutritional supplement to ensure safe consumption of these nutritional supplements. 40 participants, requiring a new pre-thickened oral nutritional supplement in line with the new IDDSI framework recruited from hospitals, outpatients clinics, care homes, community hospitals, community dietetic/speech and language therapy services or stroke rehabilitation units will receive the ready-to-use oral nutritional supplement for a 4 week intervention period. This study aims to primarily evaluate gastro-intestinal tolerance, with secondary outcomes including compliance, acceptability, nutrient intake, anthropometry and safety.

注册库
clinicaltrials.gov
开始日期
2018年8月28日
结束日期
2027年12月1日
最后更新
18天前
研究类型
Interventional
研究设计
Single Group
性别
All

研究者

责任方
Sponsor

入排标准

入选标准

  • Male or female
  • Age ≥ 18 years
  • Patients with a requirement for ≥ 250kcal/day from a milkshake style ONS for ≥ 4 weeks or current users of ONS
  • Patients identified to require mildly thick (IDDSI level 2) fluids.
  • Patients competent to provide written informed consent and able to answer questions
  • Patients able to take study ONS orally

排除标准

  • Patients that lack capacity to provide informed consent
  • Patients that are unable to take study ONS orally
  • Participants with chronic renal disease requiring dialysis
  • Participants with liver failure
  • Participants that are pregnant or lactating
  • Participation in other studies that may interfere with this study
  • Participants receiving 100% total nutritional requirements from tube feeding or parenteral nutrition
  • Patients with galactosaemia or lactose intolerance
  • Patients receiving palliative or end of life care

研究组 & 干预措施

IDDSI nutritional supplement drink

Single arm designed, 28day on IDDSI nutritional supplement drink

干预措施: IDDSI nutritional supplement drink

结局指标

主要结局

Gastrointestinal Tolerance

时间窗: Day 1, Day 2, Day 3, Day 10, Day 17, Day 24 and Day 31

Gastro-intestinal tolerance will be assessed daily throughout a 3 day baseline period before starting the study ONS and at the end of each week (day 10, day 17, day 24, day 31) using a standardised GI tolerance questionnaire including questions on number of bowel movements per day, other gastrointestinal symptoms such as flatulence, bloating, burping and abdominal discomfort. Patient-reported gastrointestinal symptoms with scale range for each symptom as s scale range minimum = none, maximum = severe. Change of symptom from baseline scale minimum = no change, maximum = worse.

次要结局

  • Nutrient intake(Day 1, Day 17 and Day 31)
  • Acceptability: Brief tick-box questionnaire(Day 1, Day 17, Day 31)
  • Compliance(Once during baseline period (Day 1) and then daily through intervention period (Days 4-31))
  • Anthropometry(Day 1 and Day 31)
  • Safety (Adverse events reporting)(31 days.)

研究点 (8)

Loading locations...

相似试验